Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.12 USD | +1.42% | +31.69% | +88.13% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
Business Summary
Number of employees: 19
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
73.2
%
| 3 | 18.6 % | 1 | 73.2 % | -58.15% |
License and Other
26.8
%
| 15 | 81.4 % | 1 | 26.8 % | -96.49% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 18 | 100.0 % | 2 | 100.0 % | -89.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Director of Finance/CFO | 40 | 17-12-31 | |
Dino Miano
COO | Chief Operating Officer | - | - |
Lisa Hegg
CTO | Chief Tech/Sci/R&D Officer | - | - |
General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
June Almenoff
BRD | Director/Board Member | 67 | 21-11-09 |
Gilla Kaplan
BRD | Director/Board Member | 76 | 20-10-11 |
Garry Neil
CEO | Chief Executive Officer | 70 | 20-01-31 |
Director/Board Member | 64 | 12-08-27 | |
Mitchell Chan
BRD | Director/Board Member | 43 | 21-11-30 |
Company contact information
Avalo Therapeutics, Inc.
540 Gaither Road Suite 400
20850, Rockville
+410-522-8707
http://www.avalotx.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+88.13% | 17.7M | |
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |
- Stock Market
- Equities
- AVTX Stock
- Company Avalo Therapeutics, Inc.